While global investors remain captivated by U.S. AI giants like Nvidia and Microsoft, a compelling value proposition may be emerging north of the border.
Several AI-focused stocks listed on the Toronto Stock Exchange (TSX) have seen significant price corrections, bringing them into focus for investors seeking grounded fundamentals. Beyond the broader AI hype, these companies share a critical trait: their AI technology is already deeply integrated into core products and demonstrably driving financial growth. This potentially offers a more favorable risk-reward profile at current levels.
Two such examples are Kinaxis Inc. and Docebo Inc., both TSX-listed Canadian tech firms specializing in AI-powered vertical software solutions. Their shares currently trade 23% and 74% below their respective all-time highs. The following analysis examines their recent performance and growth catalysts to assess their investment appeal at these levels.
With a market cap of approximately $5 billion, Kinaxis provides cloud-native, AI-driven supply chain orchestration software through its RapidResponse platform. It offers end-to-end solutions serving key global industries including aerospace, automotive, and life sciences.
The company demonstrated strong operational momentum in Q3, securing record bookings that doubled year-over-year. Major contract wins with enterprises like Renault, Repsol, and Seiko Epson underscored its competitive position. Financially, SaaS revenue grew 17% year-over-year to US$92 million, with an adjusted EBITDA margin reaching 25%. Management raised its full-year guidance for the second consecutive quarter, now projecting SaaS revenue growth between 15% and 17%.
AI is a central growth driver. Its Maestro AI agents, made generally available in Q3, are showing impressive early results, such as a 10-fold productivity gain reported by one pharmaceutical client. These capabilities are also accelerating the migration of on-premise customers to the cloud.
Analysts forecast the company’s free cash flow to expand from US$95 million in 2024 to US$260 million by 2029. If valued at 25 times forward free cash flow—a reasonable multiple—the stock could appreciate nearly 80% over the next two years.
Despite trading 74% below its peak, Docebo is showing signs of renewed business strength. In Q3, its Annual Recurring Revenue (ARR) grew 14% year-over-year to US$242.5 million. A key milestone was the early achievement of a 20% adjusted EBITDA margin, signaling a decisive shift toward profitability.
Its strategic push into the U.S. federal government market is gaining traction. Months after obtaining FedRAMP authorization in May, it secured federal customers including an expansion with the Department of Energy and a new agreement with the Air Force Cyber Academy via partner Deloitte. While navigating partner transitions, Docebo has shown resilience by signing a new five-year contract with Amazon for its healthcare division use cases. Management expressed confidence based on growing enterprise customer counts and improving retention metrics.
Analysts project its adjusted earnings per share to rise from US$1.27 in 2024 to US$2.87 by 2029. A valuation of 16 times forward earnings—close to its current multiple—suggests a potential upside of 64% over the next three years.
As Canadian leaders in applied AI, both Kinaxis and Docebo are leveraging AI to enhance product competitiveness and improve financial performance. Their significant share price pullbacks, influenced by broader market sentiment, may present a detailed evaluation window for investors focused on concrete business growth rather than generic AI narratives. Analyst projections indicate substantial potential upside, though the timing of entry should be weighed against overall market risk appetite and individual investment horizons.
